WHY ARE MANUFACTURERS LAUNCHING CLINICAL TRIALS FOR GENE THERAPY OUTSIDE THE NETHERLANDS? | Zendy

Sharon Van Norden | Zendy; Renate Bik | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

WHY ARE MANUFACTURERS LAUNCHING CLINICAL TRIALS FOR GENE THERAPY OUTSIDE THE NETHERLANDS?

Author(s) -

Sharon Van Norden,

Renate Bik

Publication year - 2020

Publication title -

amsterdam law forum

Language(s) - English

Resource type - Journals

ISSN - 1876-8156

DOI - 10.37974/alf.357

Subject(s) - theme (computing) , library science , section (typography) , law , political science , media studies , sociology , advertising , business , computer science , operating system

Why are manufacturers launching clinical trials for gene therapy outside the Netherlands? Strenuous efforts are being made around the world to develop a vaccine for the coronavirus as quickly as possible — including in the Netherlands. Recently, it was announced that Janssen Biologics, a Dutch biotechnology company, has developed a possible vaccine and it will test this vaccine no later than September of this year. Partly due to strict Dutch regulations, these tests will likely not take place in the Netherlands. What exactly is going on here? Why is this detrimental to the Netherlands?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research